RecruitingPhase 3NCT07087327

A Long-term Trial of EB-1020 in Pediatric Patients With ADHD

A Phase 3, Multicenter, Open-label, Uncontrolled, Long-term Japan-China Joint Trial to Evaluate the Safety and Efficacy of EB-1020 QD XR Capsules Administered Orally Once Daily in Children and Adolescents With Attention- Deficit/Hyperactivity Disorder

Sponsor

Otsuka Pharmaceutical Co., Ltd.

Enrollment

180 participants

Start Date

Sep 16, 2025

Study Type

INTERVENTIONAL

Conditions

Attention Deficit Hyperactivity Disorder (ADHD)

Summary

The purpose of this study is to evaluate the safety of long-term administration of mainly high doses of EB-1020 over 52 weeks in pediatric ADHD patients.

Eligibility

Min Age: 6 YearsMax Age: 17 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called EB-1020 (Centanafadine) high dose and a drug called EB-1020 (Centanafadine) low dose for people with attention deficit hyperactivity disorder (adhd). The study is currently recruiting participants at 1 location. People eligible for this study include aged 6 Years to 17 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.